lomustine has been researched along with Skin Neoplasms in 60 studies
Skin Neoplasms: Tumors or cancer of the SKIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This randomized phase II study was designed to compare the efficacy and tolerability of dacarbazine (DTIC) and bleomycin, vincristine, lomustine and DTIC (BOLD) combined with natural interferon-alpha (nIFN-alpha) or recombinant interferon-alpha2b (rIFN-alpha2b) in patients with advanced melanoma." | 9.11 | Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. ( Hahka-Kemppinen, M; Kellokumpu-Lehtinen, P; Korpela, M; Parvinen, LM; Pyrhönen, S; Seppä, H; Vuoristo, MS, 2005) |
| "40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)." | 9.07 | Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994) |
| "Forty-three patients with measurable disseminated cutaneous malignant melanoma, stages III-IV, and without previous cytotoxic chemotherapy or immunotherapy, were randomly allocated from 30 June 1980 to 30 November 1984, to receive either a schedule of procarbazine (100 mg/m2 p." | 9.06 | Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1986) |
| "Thirty-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B)." | 9.05 | Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. ( Bajetta, E; Bonadonna, G; Buzzoni, R; Nava, M; Vaglini, M; Viviani, S, 1985) |
| "Forty-four consecutive ambulatory patients (24 male, 20 female; median age, 56 years [range, 21-76]) with evaluable disseminated malignant melanoma (stages III/IV) were entered in this study from October 1, 1975, to July 21, 1980 (last follow-up, October 31, 1983); they were treated with procarbazine (100 mg/,m2 orally; maximum dose, 150 mg) on Days 1-10, vincristine (1." | 7.67 | Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1984) |
| "Twenty-one patients with Stage III malignant melanoma have been treated with a 5-day quadruple chemotherapy regime (BELD) comprising bleomycin 15 mg subcutaneously on days 1 and 4, vindesine (Eldesine) 3 mg/m2 intravenously on days 1 and 5, CCNU (lomusine) 80 mg/m2 orally on day 1, and DTIC 200 mg/m2 intravenously on days 1 through 5." | 7.67 | The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma. ( English, JS; Lever, RS; MacKie, RM; Young, DW, 1985) |
| "Sixty-five previously untreated patients with metastatic malignant melanoma were treated with lomustine, vincristine, and procarbazine." | 7.67 | Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma. ( Bodurtha, A; Iscoe, N; Paterson, A; Quirt, I; Russell, J; Shelley, W; Young, V, 1985) |
| "Fourteen consecutive melanoma patients with evaluable metastatic disease were treated with combination chemotherapy including procarbazine, vincristine and lomustine (POC)." | 7.67 | Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC). ( Ardizzoni, A; Grimaldi, A; Repetto, L; Rosso, R; Sertoli, MR, 1987) |
| "Thirty patients with disseminated cutaneous malignant melanoma were treated with a three-drug cytotoxic chemotherapy program consisting of CCNU, procarbazine, and vincristine." | 7.66 | Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup. ( Carmo-Pereira, J; Costa, FO; Henriques, E; Pimentel, P, 1980) |
| "Nine patients had brain metastases, and seven patients were systemically pretreated." | 6.68 | Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study. ( de Mulder, PH; Jansen, RL; Muller, EW; Punt, CJ; van Herpen, CM; Vreugdenhil, G, 1997) |
| "This randomized phase II study was designed to compare the efficacy and tolerability of dacarbazine (DTIC) and bleomycin, vincristine, lomustine and DTIC (BOLD) combined with natural interferon-alpha (nIFN-alpha) or recombinant interferon-alpha2b (rIFN-alpha2b) in patients with advanced melanoma." | 5.11 | Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. ( Hahka-Kemppinen, M; Kellokumpu-Lehtinen, P; Korpela, M; Parvinen, LM; Pyrhönen, S; Seppä, H; Vuoristo, MS, 2005) |
| "40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)." | 5.07 | Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994) |
| "Forty-three patients with measurable disseminated cutaneous malignant melanoma, stages III-IV, and without previous cytotoxic chemotherapy or immunotherapy, were randomly allocated from 30 June 1980 to 30 November 1984, to receive either a schedule of procarbazine (100 mg/m2 p." | 5.06 | Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1986) |
| "Thirty-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B)." | 5.05 | Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. ( Bajetta, E; Bonadonna, G; Buzzoni, R; Nava, M; Vaglini, M; Viviani, S, 1985) |
| "Accidentally, we observed a complete response (CR) in a patient undergoing chemotherapy with bleomycin, vincristine or Oncovin, CCNU or lomustine, dacarbazine (BOLD) regimen for metastatic melanoma including brain metastases, who was also treated with G-CSF to manage a concomitant leukopenia." | 3.73 | Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. ( Bonaccorsi, P; Borroni, RG; Bottoni, U; Calvieri, S; Clerico, R; Devirgiliis, V; Panasiti, V; Trasimeni, G, 2005) |
| "A chemotherapy regimen consisting of dacarbazine (DTIC), vincristine, bleomycin and lomustine (CCNU) was combined with natural leucocyte interferon (IFN) in the treatment of 37 patients with cutaneous and subcutaneous metastases of malignant melanoma." | 3.69 | Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy. ( Asko-Seljavaara, S; Hahka-Kemppinen, M; Jekunen, A; Muhonen, T; Pyrhönen, S; Virolainen, M, 1995) |
| "Forty-four consecutive ambulatory patients (24 male, 20 female; median age, 56 years [range, 21-76]) with evaluable disseminated malignant melanoma (stages III/IV) were entered in this study from October 1, 1975, to July 21, 1980 (last follow-up, October 31, 1983); they were treated with procarbazine (100 mg/,m2 orally; maximum dose, 150 mg) on Days 1-10, vincristine (1." | 3.67 | Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1984) |
| "From January 1985 to December 1987, 17 patients with advanced malignant melanoma were treated with the polychemotherapy regimen BELD (bleomycin, 15 mg subcutaneously on day 1 and 4, vindesine 3 mg/m2 intravenously on day 1 and 5, CCNU 80 mg/m2 orally on day 1 and DTIC 200 mg/m2 intravenously on day 1 through 5) proposed as effective (CR + PR 45%) and tolerable." | 3.67 | Effectiveness and toxicity of "BELD" polychemotherapy in advanced malignant melanoma. ( Cartei, G; Ceschia, T; Clocchiatti, L; Fasola, G; Galletti, D; Marsilio, P; Morandini, G; Sibau, A, 1989) |
| "Twenty-one patients with Stage III malignant melanoma have been treated with a 5-day quadruple chemotherapy regime (BELD) comprising bleomycin 15 mg subcutaneously on days 1 and 4, vindesine (Eldesine) 3 mg/m2 intravenously on days 1 and 5, CCNU (lomusine) 80 mg/m2 orally on day 1, and DTIC 200 mg/m2 intravenously on days 1 through 5." | 3.67 | The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma. ( English, JS; Lever, RS; MacKie, RM; Young, DW, 1985) |
| "Sixty-five previously untreated patients with metastatic malignant melanoma were treated with lomustine, vincristine, and procarbazine." | 3.67 | Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma. ( Bodurtha, A; Iscoe, N; Paterson, A; Quirt, I; Russell, J; Shelley, W; Young, V, 1985) |
| "Fourteen consecutive melanoma patients with evaluable metastatic disease were treated with combination chemotherapy including procarbazine, vincristine and lomustine (POC)." | 3.67 | Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC). ( Ardizzoni, A; Grimaldi, A; Repetto, L; Rosso, R; Sertoli, MR, 1987) |
| "The paper reports on a trial in which nitrosomethylurea (NMU) was compared with CCNU both in combination with vincristine and dactinomycin or the same combination with DTIC in the treatment of disseminated skin melanoma." | 3.66 | Modern problems of clinical chemotherapy of malignant tumours. ( Bychkov, MB; Perevodchikova, NI, 1980) |
| "Thirty patients with disseminated cutaneous malignant melanoma were treated with a three-drug cytotoxic chemotherapy program consisting of CCNU, procarbazine, and vincristine." | 3.66 | Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup. ( Carmo-Pereira, J; Costa, FO; Henriques, E; Pimentel, P, 1980) |
| "Twenty-six patients with mycosis fungoides were treated topically with three nitrosourea compounds: carmustine (BCNU), lomustine (CCNU), and 1-methyl-1-nitrosourea." | 3.65 | Treatment of mycosis fungoides with topical nitrosourea compounds: Further studies. ( Epstein, EH; Zackheim, HS, 1975) |
| "Nine patients had brain metastases, and seven patients were systemically pretreated." | 2.68 | Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study. ( de Mulder, PH; Jansen, RL; Muller, EW; Punt, CJ; van Herpen, CM; Vreugdenhil, G, 1997) |
| "Clinically, squamous cell carcinomas and basal cell epitheliomas are the most common cancers that occur in the Caucasian population in the United States." | 2.36 | Photocarcinogenesis, skin cancer, and aging. ( Epstein, JH, 1983) |
| "To describe a case of canine multiple cutaneous histiocytomas treated with lomustine." | 1.40 | Multiple cutaneous histiocytomas treated with lomustine in a dog. ( Colombo, S; Maina, E; Stefanello, D, 2014) |
| "Multifocal histiocytic sarcoma with a spindle-cell pattern was diagnosed based on morphologic features and intense expression of CD18." | 1.38 | Multifocal cutaneous histiocytic sarcoma in a young dog and review of histiocytic cell immunophenotyping. ( Aubry, OA; Christopherson, PW; Kennis, RA; Mastrorilli, C; Moore, PF; Newton, JC; Smith, AN; Spangler, EA; Weismann, JL, 2012) |
| "Melanoma is a highly aggressive neoplastic disease attributed to transformed melanocytes." | 1.37 | [Cellular markers based on DNA damage and repair (BER, MMR), expression of MLHI, MSH2, FasR, and cell death of lymphocytes as predictive parameters for clinical response to chemotherapy of melanoma]. ( Abramov, ME; Artamonov, DN; Gorbacheva, LB; Tronov, VA, 2011) |
| "38 cats with measurable, histologically or cytologically confirmed MCTs treated with lomustine at a dosage > or = 50 mg/m(2)." | 1.35 | Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005). ( Al-Sarraf, R; Baez, JL; Dank, G; Kristal, O; Rassnick, KM; Williams, LE; Zwahlen, CH, 2008) |
| "Procarbazine was ineffective." | 1.28 | The chemotherapeutic response of a murine (VM) model of human glioma. ( Bradford, R; Darling, JL; Thomas, DG, 1990) |
| "HN2 was a potent carcinogen, producing squamous cell carcinomas in 9 of 33 mice in 1 series." | 1.26 | Tumorigenic effect of topical mechlorethamine, BCNU and CCNU in mice. ( Smuckler, EA; Zackheim, HS, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 30 (50.00) | 18.7374 |
| 1990's | 10 (16.67) | 18.2507 |
| 2000's | 10 (16.67) | 29.6817 |
| 2010's | 10 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boostrom, BO | 1 |
| Moore, AS | 1 |
| DeRegis, CJ | 1 |
| Robat, C | 1 |
| Freeman, K | 1 |
| Thamm, DH | 1 |
| Bavcar, S | 1 |
| de Vos, J | 1 |
| Kessler, M | 1 |
| de Fornel, P | 1 |
| Buracco, P | 1 |
| Murphy, S | 1 |
| Hirschberger, J | 1 |
| Argyle, DJ | 1 |
| Doyle, AJ | 1 |
| MacDonald, VS | 1 |
| Bourque, A | 1 |
| Maina, E | 1 |
| Colombo, S | 1 |
| Stefanello, D | 1 |
| Buzás, K | 1 |
| Marton, A | 1 |
| Vizler, C | 1 |
| Gyukity-Sebestyén, E | 1 |
| Harmati, M | 1 |
| Nagy, K | 1 |
| Zvara, Á | 1 |
| Katona, RL | 1 |
| Tubak, V | 1 |
| Endrész, V | 1 |
| Németh, IB | 1 |
| Oláh, J | 1 |
| Vígh, L | 1 |
| Bíró, T | 1 |
| Kemény, L | 1 |
| Fontaine, J | 1 |
| Bovens, C | 1 |
| Bettenay, S | 1 |
| Mueller, RS | 1 |
| Malone, EK | 1 |
| Rassnick, KM | 2 |
| Wakshlag, JJ | 1 |
| Russell, DS | 1 |
| Al-Sarraf, R | 2 |
| Ruslander, DM | 1 |
| Johnson, CS | 1 |
| Trump, DL | 1 |
| Tronov, VA | 2 |
| Artamonov, DN | 2 |
| Abramov, ME | 2 |
| Gorbacheva, LB | 2 |
| Lichinitser, MR | 1 |
| Fukumoto, S | 1 |
| Hanazono, K | 1 |
| Kawasaki, N | 1 |
| Hori, Y | 1 |
| Higuchi, S | 1 |
| Sasaki, T | 1 |
| Temma, K | 1 |
| Uchide, T | 1 |
| Mastrorilli, C | 1 |
| Spangler, EA | 1 |
| Christopherson, PW | 1 |
| Aubry, OA | 1 |
| Newton, JC | 1 |
| Smith, AN | 1 |
| Kennis, RA | 1 |
| Weismann, JL | 1 |
| Moore, PF | 1 |
| Adiga, GU | 1 |
| Abebe, L | 1 |
| Wiernik, PH | 1 |
| Lens, MB | 1 |
| Eisen, TG | 1 |
| Hernberg, MM | 1 |
| Hahka-Kemppinen, MH | 1 |
| Pyrhönen, SO | 1 |
| Komori, S | 1 |
| Nakamura, S | 1 |
| Takahashi, K | 1 |
| Tagawa, M | 1 |
| Vuoristo, MS | 1 |
| Hahka-Kemppinen, M | 2 |
| Parvinen, LM | 1 |
| Pyrhönen, S | 2 |
| Seppä, H | 1 |
| Korpela, M | 2 |
| Kellokumpu-Lehtinen, P | 1 |
| Bottoni, U | 1 |
| Bonaccorsi, P | 1 |
| Devirgiliis, V | 1 |
| Panasiti, V | 1 |
| Borroni, RG | 1 |
| Trasimeni, G | 1 |
| Clerico, R | 1 |
| Calvieri, S | 1 |
| Williams, LE | 1 |
| Kristal, O | 1 |
| Baez, JL | 1 |
| Zwahlen, CH | 1 |
| Dank, G | 1 |
| Khan, MS | 1 |
| Ross, WM | 1 |
| Perevodchikova, NI | 1 |
| Bychkov, MB | 1 |
| Epstein, JH | 1 |
| Hill, GJ | 1 |
| Krementz, ET | 1 |
| Hill, HZ | 1 |
| Carmo-Pereira, J | 3 |
| Costa, FO | 3 |
| Henriques, E | 3 |
| Wheeler, KT | 1 |
| Wallen, CA | 1 |
| Wolf, KL | 1 |
| Siemann, DW | 1 |
| Robertson, DM | 1 |
| Wilkinson, CP | 1 |
| Murray, JL | 1 |
| Gordy, DD | 1 |
| Fodstad, O | 1 |
| Aass, N | 1 |
| Pihl, A | 1 |
| Pimentel, P | 1 |
| Zackheim, HS | 2 |
| Smuckler, EA | 1 |
| Vuoristo, M | 1 |
| Gröhn, P | 1 |
| Kumpulainen, E | 1 |
| Muhonen, T | 1 |
| Virolainen, M | 1 |
| Jekunen, A | 1 |
| Asko-Seljavaara, S | 1 |
| Thomas, DW | 1 |
| Lewis, MA | 1 |
| Cowpe, JG | 1 |
| Samuel, LM | 1 |
| Harvey, VJ | 1 |
| Mitchell, PL | 1 |
| Thompson, PI | 1 |
| Mak, D | 1 |
| Melville, P | 1 |
| Evans, BD | 1 |
| Punt, CJ | 1 |
| van Herpen, CM | 1 |
| Jansen, RL | 1 |
| Vreugdenhil, G | 1 |
| Muller, EW | 1 |
| de Mulder, PH | 1 |
| Carpenter, MR | 1 |
| Vassallo, M | 1 |
| Peat, IM | 1 |
| Scriven, AJ | 1 |
| Jedrzejczak, WW | 1 |
| Paciucci, PA | 1 |
| Ryder, JS | 1 |
| Mandell, JP | 1 |
| Morris, JC | 1 |
| Holland, JF | 2 |
| Chan, C | 1 |
| O'Day, J | 1 |
| Salem, PA | 1 |
| De Wasch, G | 1 |
| Bernheim, J | 1 |
| Michel, J | 1 |
| Lejeune, F | 1 |
| Kenis, Y | 1 |
| Benjamin, RS | 1 |
| Moroz, LV | 1 |
| Assekritova, IV | 1 |
| Brazhnikova, EI | 1 |
| Vaarik, KhM | 1 |
| Voznyĭ, EK | 1 |
| Carbone, PP | 1 |
| Costello, W | 1 |
| Aranha, GV | 1 |
| Grage, TB | 1 |
| Epstein, EH | 1 |
| Fiedler, H | 1 |
| Hetschko, I | 1 |
| Wohlrab, W | 1 |
| Wozniak, KD | 1 |
| Lübbe, D | 1 |
| Taube, KM | 1 |
| Barth, RJ | 1 |
| Venzon, DJ | 1 |
| Baker, AR | 1 |
| Bradford, R | 1 |
| Darling, JL | 1 |
| Thomas, DG | 1 |
| Cohen, SM | 1 |
| Ohnuma, T | 1 |
| Ambinder, EP | 1 |
| Avril, MF | 1 |
| Cartei, G | 1 |
| Ceschia, T | 1 |
| Marsilio, P | 1 |
| Clocchiatti, L | 1 |
| Fasola, G | 1 |
| Morandini, G | 1 |
| Galletti, D | 1 |
| Sibau, A | 1 |
| Young, DW | 1 |
| Lever, RS | 1 |
| English, JS | 1 |
| MacKie, RM | 1 |
| Shelley, W | 1 |
| Quirt, I | 1 |
| Bodurtha, A | 1 |
| Iscoe, N | 1 |
| Russell, J | 1 |
| Paterson, A | 1 |
| Young, V | 1 |
| Stahel, RA | 1 |
| Martz, G | 1 |
| Perevodchikova, NJ | 1 |
| Moros, LW | 1 |
| Kogonia, LM | 1 |
| Sulis, E | 1 |
| Floris, C | 1 |
| Chessa, A | 1 |
| Desogus, A | 1 |
| Muggiano, A | 1 |
| Tedde, A | 1 |
| Turno, R | 1 |
| Repetto, L | 1 |
| Grimaldi, A | 1 |
| Ardizzoni, A | 1 |
| Sertoli, MR | 1 |
| Rosso, R | 1 |
| Bajetta, E | 1 |
| Buzzoni, R | 1 |
| Viviani, S | 1 |
| Vaglini, M | 1 |
| Nava, M | 1 |
| Bonadonna, G | 1 |
| Hansson, J | 1 |
| Ringborg, U | 1 |
| Lagerlöf, B | 1 |
| Strander, H | 1 |
8 reviews available for lomustine and Skin Neoplasms
| Article | Year |
|---|---|
Canine cutaneous epitheliotropic T-cell lymphoma: a review.
Topics: Animals; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Epidermis; Female; Humans; Lomustine | 2009 |
Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bowen's Disease; Co | 2003 |
Systemic chemotherapy in the treatment of malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Clinical Trials as | 2003 |
Photocarcinogenesis, skin cancer, and aging.
Topics: Aging; Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; DNA; Humans; Lomustine; Melanoma; M | 1983 |
Melanoma-associated retinopathy: does autoimmunity prolong survival?
Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoimmun | 2001 |
Advances in cancer chemotherapy.
Topics: Bleomycin; Burkitt Lymphoma; Carcinoma, Basal Cell; Choriocarcinoma; Cyclophosphamide; Cytarabine; D | 1975 |
Chemotherapy of malignant melanoma.
Topics: Antineoplastic Agents; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Lomustine; Melan | 1979 |
[Chemotherapy of malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferons; Interleukin-2; Lom | 1988 |
13 trials available for lomustine and Skin Neoplasms
| Article | Year |
|---|---|
Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Calcitriol; Calcium Channel Agonists; | 2010 |
Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleo | 2005 |
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1984 |
Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon-alpha.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; | 1994 |
Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lomustine; Male; Melano | 1994 |
Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1997 |
Interleukin-2 plus chemotherapy for patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality | 2000 |
Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combi | 1976 |
[Results of a randomized polychemotherapy study in malignant melanoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1990 |
[Combination chemotherapy of disseminated skin melanoma with nitrosomethylurea].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Dactinomycin; | 1986 |
Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; H | 1986 |
Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic | 1985 |
Adjuvant chemotherapy of malignant melanoma. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; | 1985 |
39 other studies available for lomustine and Skin Neoplasms
| Article | Year |
|---|---|
Canine Cutaneous Plasmacytosis: 21 Cases (2005-2015).
Topics: Animals; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Drug Therapy, Combination; Female; L | 2017 |
Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dog Dise | 2017 |
Use of lomustine (CCNU) in a case of cutaneous equine lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Drug Therapy, Combinati | 2013 |
Multiple cutaneous histiocytomas treated with lomustine in a dog.
Topics: Animals; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Histiocytoma, Benign Fibrous; Lomust | 2014 |
Bacterial Sepsis Increases Survival in Metastatic Melanoma: Chlamydophila Pneumoniae Induces Macrophage Polarization and Tumor Regression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlamydophila Infections; Chlamy | 2016 |
[Cellular markers based on DNA damage and repair (BER, MMR), expression of MLHI, MSH2, FasR, and cell death of lymphocytes as predictive parameters for clinical response to chemotherapy of melanoma].
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu | 2011 |
[Effectiveness of DNA repair and expression of MLH1, MSH2 and FASR in lymphocytes of patients with chemotherapy-responsive, disseminated cutaneous melanoma].
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
Anaplastic atypical myeloma with extensive cutaneous involvement in a dog.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Fatal Outcome; Lomustin | 2012 |
Multifocal cutaneous histiocytic sarcoma in a young dog and review of histiocytic cell immunophenotyping.
Topics: Animals; Anti-Bacterial Agents; Antigens, CD; Antineoplastic Agents; Biopsy, Fine-Needle; Cephalexin | 2012 |
The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4-Positive T-Lymphocytes; | 2004 |
Use of lomustine to treat cutaneous nonepitheliotropic lymphoma in a cat.
Topics: Animals; Antineoplastic Agents, Alkylating; Cat Diseases; Cats; Fatal Outcome; Female; Lomustine; Ly | 2005 |
Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Dacarbazine | 2005 |
Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005).
Topics: Animals; Antineoplastic Agents, Alkylating; Cat Diseases; Cats; Female; Kaplan-Meier Estimate; Lomus | 2008 |
Management of malignant melanoma: a retrospective analysis of 182 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Fem | 1984 |
Modern problems of clinical chemotherapy of malignant tumours.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Carubicin; Dacarbazine; Dactinomycin; Drug Therapy, Co | 1980 |
Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lomu | 1984 |
Hypoxic cells and in situ chemopotentiation of the nitrosoureas by misonidazole.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Synergis | 1984 |
Metastatic tumor to the retina and vitreous cavity from primary melanoma of the skin: treatment with systemic and subconjunctival chemotherapy.
Topics: Adult; Carmustine; Dacarbazine; Eye Neoplasms; Female; Humans; Lomustine; Melanoma; Retina; Skin Neo | 1981 |
Response to chemotherapy of human, malignant melanoma xenografts in athymic, nude mice.
Topics: Abrin; Animals; Antineoplastic Agents; Dacarbazine; Humans; Lomustine; Melanoma; Mice; Mice, Nude; N | 1980 |
Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Leukopenia; Lomustine; Male; Melanoma; Middle Aged; | 1980 |
Tumorigenic effect of topical mechlorethamine, BCNU and CCNU in mice.
Topics: Animals; Carcinogens; Carcinoma, Squamous Cell; Carmustine; Lomustine; Mechlorethamine; Mice; Neopla | 1980 |
Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; D | 1995 |
Cutaneous T-cell lymphoma presenting as facial swelling: report of a case and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cheek; Cyclophosphamide; Etoposide; Facial Neo | 1994 |
Regression of cardiac involvement by malignant melanoma following lomustine chemotherapy.
Topics: Antineoplastic Agents; Echocardiography, Transesophageal; Female; Heart Neoplasms; Humans; Lomustine | 1997 |
[Chemotherapy of malignant melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dacarbazine; Huma | 1998 |
Combination chemotherapy with three marginally effective agents, CCNU, vincristine, and bleomycin, in the treatment of stage III melanoma.
Topics: Adolescent; Adult; Aged; Bleomycin; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lomu | 1976 |
[Combined chemotherapy of disaeminated melanoma].
Topics: Adult; Aged; Aminoimidazole Carboxamide; Antineoplastic Agents; Dactinomycin; Drug Therapy, Combinat | 1978 |
Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma.
Topics: Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Lomu | 1977 |
Treatment of mycosis fungoides with topical nitrosourea compounds: Further studies.
Topics: Administration, Topical; Adult; Aged; Bone Marrow; Carmustine; Cross Reactions; Drug Hypersensitivit | 1975 |
The prognosis of melanoma patients with metastases to two or more lymph node areas.
Topics: Adolescent; Adult; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherap | 1991 |
The chemotherapeutic response of a murine (VM) model of human glioma.
Topics: Animals; Astrocytoma; Brain Neoplasms; Carmustine; Disease Models, Animal; Lomustine; Mice; Mice, In | 1990 |
Lomustine, bleomycin, and cisplatin in patients with metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug Evaluation; | 1986 |
Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Dru | 1989 |
Effectiveness and toxicity of "BELD" polychemotherapy in advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; | 1989 |
The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administra | 1985 |
Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Diseases; Humans; L | 1985 |
[Systemic therapy of metastatic malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Immunotherapy; Interferon Type | 1988 |
Sequential treatment with interferon and chemotherapy of metastatic malignant melanoma. Total remission of cutaneous and visceral metastasis, but not of cerebral metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carmus | 1987 |
Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Female | 1987 |